TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Talaris Therapeutics Stock

Talaris Therapeutics Stock

talaristx.comHealthcareFounded: 1900Funding to Date: $100MM

Talaris Therapeutics is a late-clinical stage biotechnology company developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders.

Learn more about Talaris Therapeutics IPO
Register for Details

For more details on financing and valuation for Talaris Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Talaris Therapeutics.

Register Today

Team

Management Team

Nancy Krieger MD
Chief Medical Officer
Francois Nader
Chairman
Suzanne Ildstad MD
Founder, Board Member & Chief Scientific Officer
Scott Requadt JD
Chief Executive Officer & Board Member

Board Members

Geoff MacKay
Sandip Agarwala
Longitude Capital
Mark McDade
Qiming Venture Partners
Scott Requadt JD
Suzanne Ildstad MD
Francois Nader
Nicholas Galakatos Ph.D
Blackstone Life Sciences

Other companies like Talaris Therapeutics in the Healthcare sector

Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
Acelyrin
Sector
Healthcare
Last Round Est. Valuation
$809.52MM
Paradromics
Sector
Healthcare
 
 
Colossal Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.01B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
OURA
Sector
Healthcare
 
 
Alzheon
Sector
Healthcare
Last Round Est. Valuation
$1.53B
Artera
Sector
Healthcare
Last Round Est. Valuation
$396.01MM

News

Business Wire 04/18/2019
Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development
The series A funding will be used to advance Talaris' proprietary, one-time, allogeneic cell therapy, FCR001, into later-stage clinical development.
FinSMEs 04/18/2019
Talaris Therapeutics Raises $100M in Series A Financing | FinSMEs
Talaris Therapeutics, which develops cell therapies with potential to eliminate chronic immunosuppression for organ transplant recipients, raised $100m

Trending Companies

Frequently Asked Questions

Updated on: Jun 8, 2023